Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Company Profile - Simbec Orion Group Ltd

Simbec Orion Group Ltd

Simbec Orion Group Ltd profile logo

Head Office

Merthyr Tydfil Industrial Park Cardiff Road Merthyr Tydfil

CF48 4DR

Tel: +44 1443 690977



Simbec-Orion Group Limited (“Simbec-Orion” or the “Group”) was created in June 2014 by the merger of Simbec Research Limited (“Simbec”) and Orion Clinical Services Limited (“Orion”). 


As a result of the merger, Simbec-Orion is today a full service CRO covering first in human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies.  Simbec-Orion supports its clients with our own in-house full service central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy, medical management.  We have expertise in all drug types, dosage forms and delivery mechanisms and in later stage development and have six core therapeutic disciplines:


•           oncology,

•           rare and orphan diseases,

•           respiratory disorders,

•           dermatology,

•           infectious disease & vaccines, and

•           translational medicine. 


We operate internationally serving clients anywhere in the world with physical operations in the United Kingdom, France, Germany, Italy, Spain, Czech Republic, Poland, Australia, South Africa and the United States of America.  We have a combined staff approaching 250 people with the greatest concentrations in the UK and France.


It is our objective to become widely recognised as being a significant international full service CRO known for its excellence both across its range of services and in its therapeutic disciplines.  We compete effectively against many of our larger competitors by offering a broader range of services and with greater depth of knowledge in our chosen therapeutic areas. 


Given the background of a number of our senior leadership team, we think with the same focus as our clients - as drug developers and not simply as outsource service providers.  Our goal is to meet their actual needs and not simply execute a study.


Our growth targets aim to see the Group grow from its current size of approximately revenues of £25m ($37m) per annum to £100m ($150m).  This will be achieved in part by organic growth but also through further M&A activity.


Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.